文献速递泌尿生殖与妇科肿瘤放疗

新辅助放化疗后行筋膜外子宫切除术治疗临床延伸至宫颈的局部晚期II型子宫内膜癌

Neoadjuvant Chemoradiation Therapy Followed by Extrafascial Hysterectomy in Locally Advanced Type II Endometrial Cancer Clinically Extending to Cervix.
PubMed 文献 · Pract Radiat Oncol · 2019-02-22

回顾性分析34例临床证据提示宫颈±宫旁受累的II型子宫内膜癌患者,接受新辅助外照射放疗(45-50.4 Gy/25-28次)和高剂量率近距离放疗(中位总剂量20 Gy,范围15-27.5 Gy,4次,范围3-5次)及同步铂类化疗±辅助化疗。94%患者降期至可行筋膜外子宫切除术,94%手术切缘阴性。2年局部控制率87.8%、区域控制率81.3%、远处控制率76.3%、无病生存率52.5%、总生存率63.7%。

要点

  • 94%的局部晚期II型子宫内膜癌患者经新辅助放化疗后降期至可行筋膜外子宫切除术。
  • 94%患者手术切缘阴性。
  • 2年局部控制率87.8%、区域控制率81.3%、远处控制率76.3%、无病生存率52.5%、总生存率63.7%。

核心结论

  • 新辅助放化疗有效使大多数局部晚期II型子宫内膜癌降期,从而提高实现完整切除且切缘阴性的可能性。

研究设计与样本

  • 回顾性分析2008年至2018年34例临床证据提示宫颈±宫旁受累的II型子宫内膜癌患者,接受新辅助外照射放疗(45-50.4 Gy/25-28次)和高剂量率近距离放疗(中位总剂量20 Gy,范围15-27.5 Gy,4次,范围3-5次)及同步铂类化疗±辅助化疗。
  • 排除I型病理诊断者和接受根治性(而非术前)治疗意图者。

主要发现

  • 病理类型:38%为癌肉瘤,18%为浆液性,24%为透明细胞。
  • 94%患者降期至可行筋膜外子宫切除术,94%手术切缘阴性。
  • 2年局部控制率87.8%、区域控制率81.3%、远处控制率76.3%、无病生存率52.5%、总生存率63.7%。
  • 1例亚急性3级和1例晚期3级小肠梗阻,直接归因于放疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The role of neoadjuvant chemoradiation therapy in locally advanced type II endometrial cancer is controversial. We thus aimed to present our experience with the hypothesis that neoadjuvant chemoradiation therapy is associated with similarly high rates of downstaging and locoregional control for type II endometrial cancer and type I endometrial cancer. METHODS AND MATERIALS: Thirty-four patients with type II endometrial cancer with clinical evidence of cervical ± parametrium involvement treated with neoadjuvant external beam radiation therapy (45-50.4 Gy in 25-28 fractions) and high-dose-rate brachytherapy with a median total dose of 20 Gy (range, 15-27.5) in 4 fractions (range, 3-5) and concurrent platinum chemotherapy ± adjuvant chemotherapy from 2008 to 2018 were retrospectively reviewed. Patients with type I pathologic diagnoses and those treated with definitive (rather than preoperative) intent were excluded. RESULTS: Pathologic characteristics were as follows: 38% were carcinosarcoma, 18% serous, and 24% clear cell. Ninety-four percent of patients were downstaged to an extrafascial hysterectomy, and 94% had negative surgical margins. The 2-year local control, regional control, distant control, disease-free survival, and overall survival were 87.8%, 81.3%, 76.3%, 52.5%, and 63.7%, respectively. There was 1 subacute grade 3 and 1 late grade 3 small bowel obstruction, directly attributable to radiation therapy. CONCLUSIONS: Neoadjuvant chemoradiation therapy effectively downstages the majority of locally advanced type II endometrial cancers, thereby increasing the likelihood of achieving complete resection with negative margins.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Iheagwara UK, Vargo JA, Chen KS, et al. Neoadjuvant Chemoradiation Therapy Followed by Extrafascial Hysterectomy in Locally Advanced Type II Endometrial Cancer Clinically Extending to Cervix. Pract Radiat Oncol. 2019. PMID: 30802615. doi:10.1016/j.prro.2019.02.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。